DTC guidance comment extension
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders have until Aug. 10 to submit comments on FDA's February direct-to-consumer advertising guidances (1"The Gray Sheet" Feb. 9, 2004, p. 6). The comment period had closed May 10, but FDA opted to reopen it after receiving "numerous requests" for more time, including a plea from AdvaMed and a memo from FDA's Division of Drug Marketing, Advertising & Communications on behalf of the drug industry...
You may also be interested in...
Device DTC Guidances Aim To Hone Enforcement, Stimulate Patient Education
FDA's draft guidances for consumer advertising establish explicit standards to which the agency will hold medical device manufacturers accountable, according to Commissioner Mark McClellan
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.